Biotech

Biotech Andrew Joseph

STAT Plus: FDA approves innovative T cell immunotherapy for rare soft-tissue cancer

Adam's Biotech Scorecard Adam Feuerstein

STAT Plus: On Andrew Left and the government’s fraud case

Biotech Andrew Joseph

STAT Plus: Jim Wilson, gene therapy pioneer, departs Penn to set up new companies

The Readout Elaine Chen

STAT Plus: venBio raises $528 million for its fifth fund

Biotech Adam Feuerstein

STAT Plus: With new data, Regenxbio advances plan for Duchenne gene therapy

Biotech Elaine Chen

STAT Plus: Eli Lilly’s obesity drug Zepbound shows benefits in heart failure patients

Health tech Matthew Herper

STAT Plus: 23andMe co-founder Anne Wojcicki files proposal to take company private

The Readout Elaine Chen

STAT Plus: The debate over how long to use Alzheimer’s drugs

First Opinion Radoje Drmanac

STAT Plus: DNA data security requires robust protections, not rhetoric

Biotech Elaine Chen and Adam Feuerstein

STAT Plus: Eisai, Biogen make case for long-term use of Alzheimer’s drug Leqembi with new data

Biotech Elaine Chen

STAT Plus: Merck shares fall after drop in China HPV vaccine sales

The Readout Elaine Chen

STAT Plus: Testing GLP-1s in Alzheimer’s, and is Medicare a good negotiator?

Biotech Elaine Chen

STAT Plus: Older GLP-1 drug may help protect brains of Alzheimer’s patients, early study suggests

Biotech Matthew Herper

STAT Plus: In a big step for liquid biopsy, FDA approves a blood screening test for colorectal cancer

The Readout Meghana Keshavan

STAT Plus: The biotech news you need from the weekend

Exclusive Adam Feuerstein

STAT Plus: Sarepta demanded Duchenne patient advocacy group censor video critical of the company

The Readout Elaine Chen

STAT Plus: The worst for Dexcom may not be over

Biotech Andrew Joseph

STAT Plus: European regulators say Alzheimer’s therapy Leqembi should be rejected

Pharma Jason Mast

STAT Plus: How Pfizer’s grand gene therapy ambitions crumbled

The Readout LOUD Elaine Chen, Adam Feuerstein, and Allison DeAngelis

STAT Plus: UnitedHealth’s doctor empire, an FDA departure, and Viking’s obesity moves

Biotech Andrew Joseph

STAT Plus: Roche CEO explains the company’s weight loss drug strategy in crowded market

Health tech Mario Aguilar

STAT Plus: Six questions about Medicare’s proposed plan to cover digital therapeutics

Adam's Biotech Scorecard Adam Feuerstein

STAT Plus: A preview of Neurocrine’s muscarinic drug readout

The Readout Meghana Keshavan

STAT Plus: A potential rival for Wegovy and Zepbound enters the fray

Biotech Elaine Chen

STAT Plus: Viking accelerates development of obesity drug that could rival Wegovy, Zepbound

The Readout Elaine Chen

STAT Plus: Merck lays off workers amid rough pharma job market

Biotech Adam Feuerstein

STAT Plus: Sage suffers pipeline setback with failure of drug to treat essential tremor

Pharma Jason Mast

STAT Plus: Pfizer gene therapy reduced hemophilia bleeds, but questions remain

The Readout Elaine Chen

STAT Plus: Contradictory coverage decisions in North Carolina